Navigation Links
Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma
Date:5/5/2009

EVRY, France, May 5 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announces today that the Company's Investigational New Drug Application (IND) to conduct a Phase III clinical trial of Catioprost(R) (Nova21027), for the treatment of glaucoma has been granted by the U.S. Food and Drug Administration (FDA). Catioprost(R) is a topical ocular proprietary BAK-free formulation of latanoprost which furthermore benefits from the ocular surface protection properties of Novasorb(R), its patented technology based on cationic emulsion.

Novasorb(R) properties have already been clinically validated through Cationorm(R) a marketed product for dry eye symptoms relief and Cyclokat(R), a pharmaceutical product in phase III for the treatment of moderate to severe dry eye.

Glaucoma is a group of diseases that can damage the eye's optic nerve and result in vision loss and blindness. It is estimated that more than 65 million people worldwide suffer from glaucoma, 4 million of whom in the US.

For these patients treated on a long term basis, toxicity of preservatives is a major concern. In fact the prevalence of ocular surface disease in glaucoma patients is estimated to be ranging from 30 to 70% depending on definition and severity. Coexistence of glaucoma and ocular surface disorder may impact vision related quality of life.

Catioprost(R) is a topical ocular BAK-free emulsion of latanoprost that present a safer profile than BAK-containing marketed products for glaucoma. This is a major advantage since it is admitted that BAK exerts toxicity after long term use and that glaucoma is a chronic disease needing life-long daily treatment. Furthermore, the stability product profile allows storage at room temperature.

The FDA agreed that Novagali may proceed with a pivotal Phase III clinical trial in the United States with Catioprost(R) in patients with glaucoma
'/>"/>

SOURCE Novagali Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
2. Novagali Pharma Completes a EUR15 Million Fund Raising
3. Novagali Pharma Announces the Launch of Cationorm(R)
4. Fifth Annual SemTech Conference Highlights How Semantics Power Chemistry, Pharmaceutical, Healthcare, and Other Life Science Solutions
5. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
6. Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
7. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
8. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
9. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
10. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/19/2014)... The Latin American hardware encryption display market report defines ... and forecast of revenue. This market was valued at ... $2,366.8 million by 2018, at a CAGR of 70.3% ... of the Latin American hardware encryption market report to ... also provides a glimpse of the segmentation of the ...
(Date:10/19/2014)... October 19, 2014 The Asia-Pacific Speech ... market in Asia-Pacific with analysis and forecast of revenue. ... in 2014 to $208 million by 2019, at a ... to 2019. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
(Date:10/18/2014)... October 19, 2014 The “Human ... Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid ... Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to ... drivers, restraints, challenges, opportunities, current market trends, and ... with the estimates and forecasts of the revenue ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... US Oncology, Inc . announced that ... counsel, will be departing from the Company, effective November 30, ... had a long and rich history with US Oncology. Beginning ... and consultation as an outside attorney before joining the Company ...
... ST. LOUIS, Nov. 10 At the Board of Directors ... of $.145 per share, an 11.5% increase over the prior ... to shareholders of record on December 1, 2009. , ... Science and High Technology company. Our chemical and biochemical products ...
... Helix Consulting US, a division of London-based Double ... Michael Rizzo to the position of Vice President. ... experienced strategic pricing, reimbursement and market access consultants ... provides product commercialization services to firms in the ...
Cached Biology Technology:US Oncology Announces Retirement of General Counsel Phil Watts 2Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President 2Double Helix Consulting Enhances its Strategic Product Commercialization Services with Appointment of Michael Rizzo as Vice President 3
(Date:10/17/2014)... knowledge regarding Ebola is critical and pertinent for practicing ... global outbreak and epidemic. The Journal, Disaster Medicine ... issue, Ebola Virus and Public Health, to surround the ... this critical societal moment. , On October 17, ... Clinicians . The primer was prepared by Dr. Eric ...
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
... of dinosaur unearthed in Mexico is giving scientists fresh insights ... an international research team led by scientists from the Utah ... To date, the dinosaur record from Mexico has been sparse, ... Natural History, Utahs designated natural history museum. The new ...
... HANOVER, N.H. Dartmouth College researchers and colleagues from ... the beginnings of complex life, i.e. vertebrates, to microRNA. ... regulate gene expression, are behind the origin of early ... to understanding the evolutionary origin of our own lineage, ...
... goal of Raphael Kopan, Ph.D., professor of molecular biology ... The moss plant (Physcomitrella patens) studied in the ... Professor and chair of the WUSTL biology department on ... Heres how. The gene presenilin in mammals ...
Cached Biology News:New dinosaur from Mexico offers insights into ancient life on West America 2New dinosaur from Mexico offers insights into ancient life on West America 3New dinosaur from Mexico offers insights into ancient life on West America 4New dinosaur from Mexico offers insights into ancient life on West America 5New dinosaur from Mexico offers insights into ancient life on West America 6Dartmouth researchers find the root of the evolutionary emergence of vertebrates 2Moss protein plays role in Alzheimer's disease 2Moss protein plays role in Alzheimer's disease 3Moss protein plays role in Alzheimer's disease 4